No scope of US intervention in Indian pharma cos: Wockhardt

No scope of US intervention in Indian pharma cos: Wockhardt
12-Jan-2017 01:07 MONEYCONTROL

Wockhardt chief Habil Khorakiwala says that Indian generic company as a whole is a competitive industry in US and therefore there is no scope for government intervention there. Anmol Ganjoo of JM Financial says if drug prices come down then Indian pharma companies will benefit.